Vestmark Advisory Solutions Inc. Sells 99 Shares of Humana Inc. (NYSE:HUM)

Posted by Defense World Staff on Apr 2nd, 2023

Vestmark Advisory Solutions Inc. lowered its stake in shares of Humana Inc. (NYSE:HUM – Get Rating) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,207 shares of the insurance provider’s stock after selling 99 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Humana were worth $1,131,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hellman Jordan Management Co. Inc. MA boosted its holdings in Humana by 4.9% during the fourth quarter. Hellman Jordan Management Co. Inc. MA now owns 2,679 shares of the insurance provider’s stock worth $1,372,000 after buying an additional 125 shares during the last quarter. HB Wealth Management LLC boosted its holdings in Humana by 4.4% during the fourth quarter. HB Wealth Management LLC now owns 2,998 shares of the insurance provider’s stock worth $1,536,000 after buying an additional 126 shares during the last quarter. Affiance Financial LLC acquired a new stake in shares of Humana during the fourth quarter worth about $50,000. Crossmark Global Holdings Inc. raised its position in shares of Humana by 22.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 13,281 shares of the insurance provider’s stock worth $6,803,000 after purchasing an additional 2,477 shares during the period. Finally, Arlington Partners LLC acquired a new stake in shares of Humana during the fourth quarter worth about $29,000. Institutional investors own 93.38% of the company’s stock.

Humana Stock Down 0.6 %

NYSE:HUM opened at $485.46 on Friday. The firm has a market capitalization of $60.67 billion, a price-to-earnings ratio of 22.03, a price-to-earnings-growth ratio of 1.22 and a beta of 0.72. Humana Inc. has a twelve month low of $410.87 and a twelve month high of $571.30. The stock’s 50 day moving average price is $495.58 and its two-hundred day moving average price is $508.37. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59.

Humana (NYSE:HUM – Get Rating) last posted its quarterly earnings results on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.16. The firm had revenue of $22.44 billion for the quarter, compared to analyst estimates of $22.45 billion. Humana had a return on equity of 20.50% and a net margin of 3.02%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.24 EPS. Equities research analysts expect that Humana Inc. will post 28.05 earnings per share for the current fiscal year.

Humana Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be given a dividend of $0.885 per share. This is a positive change from Humana’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Thursday, March 30th. This represents a $3.54 annualized dividend and a dividend yield of 0.73%. Humana’s payout ratio is 14.29%.

Insiders Place Their Bets

In other Humana news, CEO Bruce D. Broussard sold 17,575 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total transaction of $8,890,313.75. Following the transaction, the chief executive officer now owns 70,040 shares of the company’s stock, valued at approximately $35,429,734. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Joseph C. Ventura sold 2,048 shares of Humana stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $507.97, for a total transaction of $1,040,322.56. Following the completion of the transaction, the insider now directly owns 4,256 shares in the company, valued at approximately $2,161,920.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 17,575 shares of Humana stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $505.85, for a total value of $8,890,313.75. Following the transaction, the chief executive officer now owns 70,040 shares of the company’s stock, valued at $35,429,734. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on HUM shares. Stephens dropped their price target on Humana from $625.00 to $590.00 and set an “overweight” rating on the stock in a research report on Friday, February 3rd. JPMorgan Chase & Co. dropped their price target on Humana from $630.00 to $625.00 and set an “overweight” rating on the stock in a research report on Friday, January 6th. Cowen dropped their price target on Humana from $647.00 to $581.00 and set an “outperform” rating on the stock in a research report on Monday, February 6th. Deutsche Bank Aktiengesellschaft dropped their price target on Humana from $575.00 to $562.00 and set a “buy” rating on the stock in a research report on Tuesday, February 28th. Finally, Credit Suisse Group dropped their price target on Humana from $635.00 to $575.00 and set an “outperform” rating on the stock in a research report on Monday, February 6th. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Humana currently has a consensus rating of “Moderate Buy” and a consensus target price of $594.12.

Humana Company Profile

(Get Rating)

Humana Inc engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Get Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.